CN101501694B - 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法 - Google Patents

用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法 Download PDF

Info

Publication number
CN101501694B
CN101501694B CN2007800290322A CN200780029032A CN101501694B CN 101501694 B CN101501694 B CN 101501694B CN 2007800290322 A CN2007800290322 A CN 2007800290322A CN 200780029032 A CN200780029032 A CN 200780029032A CN 101501694 B CN101501694 B CN 101501694B
Authority
CN
China
Prior art keywords
protein
amino acid
peptide
residue
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800290322A
Other languages
English (en)
Chinese (zh)
Other versions
CN101501694A (zh
Inventor
卡伊·J·科尔霍夫
赫苏斯·苏尔多
米凯莱·文德鲁斯科洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza Biologics PLC
Original Assignee
Lonza Biologics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Biologics PLC filed Critical Lonza Biologics PLC
Publication of CN101501694A publication Critical patent/CN101501694A/zh
Application granted granted Critical
Publication of CN101501694B publication Critical patent/CN101501694B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
CN2007800290322A 2006-08-04 2007-07-24 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法 Expired - Fee Related CN101501694B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82155306P 2006-08-04 2006-08-04
US60/821,553 2006-08-04
PCT/GB2007/002789 WO2008015384A1 (en) 2006-08-04 2007-07-24 Method for predicting protein aggregation and designing aggregation inhibitors

Publications (2)

Publication Number Publication Date
CN101501694A CN101501694A (zh) 2009-08-05
CN101501694B true CN101501694B (zh) 2011-11-30

Family

ID=38573441

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800290322A Expired - Fee Related CN101501694B (zh) 2006-08-04 2007-07-24 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法

Country Status (11)

Country Link
US (1) US8290713B2 (https=)
EP (1) EP2047393A1 (https=)
JP (1) JP2009545756A (https=)
KR (1) KR20090047470A (https=)
CN (1) CN101501694B (https=)
AU (1) AU2007280282B2 (https=)
CA (1) CA2657847A1 (https=)
EA (1) EA016884B1 (https=)
IL (1) IL196551A (https=)
SG (1) SG173405A1 (https=)
WO (1) WO2008015384A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108780098A (zh) * 2016-01-06 2018-11-09 剑桥企业有限公司 基于化学动力学识别新型蛋白质聚集抑制剂的方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
GB2455102A (en) * 2007-11-28 2009-06-03 Cambridge Entpr Ltd Protein Aggregation Prediction Systems
WO2009128948A1 (en) 2008-04-17 2009-10-22 Peptimmune, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
CN107677828A (zh) * 2008-10-31 2018-02-09 耶鲁大学 子痫前期检测和治疗的方法和组合物
AU2010310895A1 (en) * 2009-10-23 2012-05-03 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20120108904A1 (en) * 2010-10-20 2012-05-03 Yong Ma Cleaner for endoscope
CN103772487B (zh) * 2012-10-24 2015-11-25 国家纳米科学中心 一种抑制人胰淀素聚集或毒性的多肽、试剂及其应用
US9618524B2 (en) * 2014-03-26 2017-04-11 Plaxgen Inc. Method, composition, isolation and identification of a plaque particle and related biomarker
CN104502219B (zh) * 2014-12-18 2017-09-29 江苏大学 一种淀粉样多肽聚集抑制剂及其抑制效果评估和验证方法
EP3242955B1 (en) 2015-01-06 2020-05-06 North Carolina State University Modeling ribosome dynamics to optimize heterologous protein production
CA3011719A1 (en) * 2016-01-21 2017-07-27 Protein Dynamic Solutions Llc Method and system for spectral data analysis
US10815271B2 (en) * 2016-06-29 2020-10-27 The Regents Of The University Of California Structure-based peptide inhibitors of alpha-synuclein aggregation
CN106501550A (zh) * 2016-12-09 2017-03-15 江苏大学 基于原子力显微镜氨基酸影响鱼蛋白聚集行为的评价方法
CN111653310B (zh) * 2020-06-29 2023-06-20 北京大学深圳研究生院 含二硫键多肽的结构预测方法及装置

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU781044B2 (en) * 1999-11-05 2005-05-05 Axonyx, Inc. Peptide analogs and mimetics suitable for in vivo use in the treatment of diseases associated with abnormal protein folding into amyloid, amyloid-like deposits or beta-sheet rich pathological precursor thereof
CA2528627A1 (en) * 2003-06-23 2005-01-06 Neurochem (International) Limited Treatment of protein aggregation disorders
GB0325817D0 (en) 2003-11-05 2003-12-10 Univ Cambridge Tech Method and apparatus for assessing polypeptide aggregation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE GROOT NATALIA SANCHEZ.Prediction of "hot sports" of aggregation in disease-linked polypeptides.《BMC STRUCTURAL BIOLOGY》.2005,第5卷(第1期), *
PAWAR A P.Prediction of "Aggregation-prone"and "Aggregation-susceptible"Regions in Proteins Associated with Neurodegenerative Diseases.《JOURNAL OF MOLECULAR BIOLOGY》.2005,第350卷(第2期), *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108780098A (zh) * 2016-01-06 2018-11-09 剑桥企业有限公司 基于化学动力学识别新型蛋白质聚集抑制剂的方法
CN108780098B (zh) * 2016-01-06 2021-12-17 剑桥企业有限公司 基于化学动力学识别新型蛋白质聚集抑制剂的方法

Also Published As

Publication number Publication date
WO2008015384A1 (en) 2008-02-07
IL196551A0 (en) 2009-11-18
AU2007280282A1 (en) 2008-02-07
EA200970180A1 (ru) 2009-08-28
JP2009545756A (ja) 2009-12-24
SG173405A1 (en) 2011-08-29
AU2007280282B2 (en) 2012-02-02
CA2657847A1 (en) 2008-02-07
CN101501694A (zh) 2009-08-05
US20100160602A1 (en) 2010-06-24
EA016884B1 (ru) 2012-08-30
IL196551A (en) 2013-01-31
US8290713B2 (en) 2012-10-16
WO2008015384A8 (en) 2008-05-15
KR20090047470A (ko) 2009-05-12
HK1131239A1 (en) 2010-01-15
EP2047393A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
CN101501694B (zh) 用于对蛋白质聚集进行预测以及设计聚集抑制剂的方法
Teixeira et al. IDPConformerGenerator: a flexible software suite for sampling the conformational space of disordered protein states
Shell et al. A test on peptide stability of AMBER force fields with implicit solvation
Louros et al. Structure-based machine-guided mapping of amyloid sequence space reveals uncharted sequence clusters with higher solubilities
Man et al. Effects of all-atom molecular mechanics force fields on amyloid peptide assembly: the case of aβ16–22 dimer
Jana et al. Presence of a SARS-CoV-2 protein enhances amyloid formation of serum amyloid A
Sommer et al. Structure-guided isoform identification for the human transcriptome
Jain et al. Hierarchical folding free energy landscape of HP35 revealed by most probable path clustering
Louros et al. Mapping the sequence specificity of heterotypic amyloid interactions enables the identification of aggregation modifiers
Stein et al. Novel peptide-mediated interactions derived from high-resolution 3-dimensional structures
US20230245725A1 (en) Means and Methods for the Prediction of Amyloid Core Sequences
Fatafta et al. A brief history of amyloid aggregation simulations
Orr et al. Uncovering the Binding and Specificity of β-Wrapins for Amyloid-β and α-Synuclein
Hong et al. Rare disease genomics and precision medicine
Robinson et al. Are AMBER force fields and implicit solvation models additive? A folding study with a balanced peptide test set
Szczepski et al. AlphaFold and what is next: bridging functional, systems and structural biology
Linh et al. Impact of mutations at C-terminus on structures and dynamics of Aβ40 and Aβ42: a molecular simulation study
Das et al. Rational design of protein-specific folding modifiers
Huang et al. Unveiling medin folding and dimerization dynamics and conformations via atomistic discrete molecular dynamics simulations
Ringeval et al. DeTox: a pipeline for the detection of toxins in venomous organisms
Yuwen et al. Role of electrostatic interactions in binding of peptides and intrinsically disordered proteins to their folded targets: 2. The model of encounter complex involving the double mutant of the c-Crk N-SH3 domain and peptide Sos
Sitarik et al. A widespread protein misfolding mechanism is differentially rescued in vitro by chaperones based on gene essentiality
Tsiolaki et al. Mining databases for protein aggregation: a review
Zganec et al. Assembly of stefin B into polymorphic oligomers probed by discrete molecular dynamics
Gan et al. Benchmarking ensemble docking methods in D3R Grand Challenge 4

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131239

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131239

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111130

Termination date: 20140724

EXPY Termination of patent right or utility model